Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04207151 · ClinicalTrials.gov registry record · NA

Expanding PrEP By Embedding Unannounced SNAPS Navigators in High STI Testing Clinical Sites

A NA study of HIV and Sexually Transmitted Infection, sponsored by NYU Langone Health.

Completed
Registry status
NA
Development phase
200
Enrollment target
1
Study location

NCT04207151: Completed NA study of HIV and Sexually Transmitted Infection, sponsored by NYU Langone Health.

NCT04207151 is a NA study of HIV and Sexually Transmitted Infection that has completed, run by NYU Langone Health. The registered enrollment target is 200 participants, below the 439-participant average among 303 other HIV trials with a reported enrollment target (54% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04207151, a NA study of HIV and Sexually Transmitted Infection, has completed, sponsored by NYU Langone Health.

COMPLETED
Registry status
NA
Development phase
200 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to assess the impact of an intervention, known as SNAPS, to expand Preexposure Prophylaxis (PrEP) prescriptions at Health + Hospitals (H+H)/Bellevue. In addition, evaluating whether this intervention, ie SNAPS, helps patients get on PrEP and stay on PrEP to prevent STIs like HIV. PrEP is a medication that needs to be taken on a regular basis in order to be effective to prevent HIV transmission.

Primary Outcome

Change in rate of PrEP prescriptions at H+H/Bellevue among those in care for 1-year before study period and during 1-year study period by gender, race/ethnicity, age, insurance type, and preferred language.

Interventions

  • BEHAVIORAL SNAPS intervention

Study Locations (1)

New York

  • NYU Langone - New York

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2019-07-22
Est. Completion 2023-01-09
Phase NA
NYU Langone Health

1,164 total trials

What the finished NCT04207151 record still lists

NCT04207151 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 439-participant average among 303 other HIV trials with a reported enrollment target (54% lower).

The record links to 2 conditions, with HIV appearing as the primary indexed condition, and to 1 intervention - of which SNAPS intervention is the first listed.

NCT04207151 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT04207151 about?

NCT04207151 is a clinical study titled "Expanding PrEP By Embedding Unannounced SNAPS Navigators in High STI Testing Clinical Sites". The goal of this study is to assess the impact of an intervention, known as SNAPS, to expand Preexposure Prophylaxis (PrEP) prescriptions at Health + Hospitals (H+H)/Bellevue. In addition, evaluating whether this intervention, ie SNAPS, helps patients get on PrEP and stay on PrEP to prevent STIs lik...

What is the current status of trial NCT04207151?

This trial is currently completed. It is a NA study. The enrollment target is 200 participants. The study started on 2019-07-22. Estimated completion is 2023-01-09.

What conditions does trial NCT04207151 study?

This clinical trial studies the following conditions: HIV, Sexually Transmitted Infection.

What interventions are being tested in trial NCT04207151?

The interventions under investigation include: SNAPS intervention (BEHAVIORAL).

Who is sponsoring clinical trial NCT04207151?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04207151 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for HIV

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04207151's enrollment target sits among peer trials

200 103rd of 303 higher than 188 of 303 other HIV trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other HIV trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00107289 · 200 participants · Phase 2

    Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

  • NCT00109174 · 200 participants · NA

    MRS Measurement of Glutamate and GABA Metabolism in Brain

  • NCT00177268 · 200 participants

    Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

  • NCT00493688 · 200 participants

    A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04207151, the US trial registry maintained by the National Library of Medicine. NCT04207151 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.